Aldeyra Therapeutics Announces FDA Appeal; Extends Cash Runway

What Happened
On September 29, 2026 Aldeyra Therapeutics, Inc. filed an 8-K disclosing that, following a Type D meeting with the FDA on September 25, 2026, the company intends to submit a Formal Dispute Resolution Request (FDRR) to the FDA’s Office of New Drugs (OND) to appeal the March 16, 2026 Complete Response Letter (CRL) that denied approval of reproxalap for dry eye disease. Aldeyra said the FDRR submission and a meeting with the OND are expected in the fourth quarter of 2026. The company also announced an extension of its projected operational cash runway into 2029 and held a conference call on September 29, 2026; a presentation referenced on the call was furnished as an exhibit.

Key Details

• CRL received: March 16, 2026 (denial of reproxalap New Drug Application for dry eye disease).
• Type D meeting with FDA: September 25, 2026.
• Next steps: FDRR filing and OND meeting expected in Q4 2026.
• Financial update: Aldeyra projects its operational cash runway extended into 2029.

Why It Matters
This 8-K identifies the company’s formal next regulatory step—an appeal via an FDRR—and sets a near-term timeline (Q4 2026) for engagement with the FDA’s OND, which is a key catalyst for reproxalap’s approval prospects. The stated extension of the cash runway into 2029 is a material update for investors because it affects near-term financing needs and operational planning. Investors should watch for the FDRR filing, the OND meeting outcome, and subsequent FDA communications for information that could materially affect Aldeyra’s development program and valuation.